Cambridge, United States
Casma Therapeutics, founded in 2018 and headquartered in the United States, is shaping the future of the Biotechnology and Health Care industries through innovative research. With the slogan, "Harnessing the power of autophagy to bring cures to patients with serious diseases," the company focuses on utilizing the natural cellular process of autophagy to create groundbreaking medicines aimed at treating a wide array of ailments.
Casma Therapeutics most recently secured a substantial $46.00M Series C investment on 15 November 2022. This round of funding reflects significant confidence from prominent investors, including Amgen Ventures, Mirae Asset, The Column Group, Third Rock Ventures, Astellas Venture Management, Eisai, Euclidean Capital, Ono Venture Investment, Schroders Capital, and Eventide Management Partners. These backers underscore a strong belief in Casma's potential to revolutionize medical treatment through its distinct approach to drug development.
